Arcus Biosciences, Inc.
NYSE:RCUS · New York Stock Exchange
-$0.09 today
Vol 1.12M · Avg 1.17M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $201.0M |
| Short-term Investments | $621.0M |
| Receivables | $7.0M |
| Other Current | $15.0M |
| Total Current Assets | $844.0M |
| PP&E (Net) | $38.0M |
| Long-term Investments | $54.0M |
| Other Non-current | $61.0M |
| Total Non-current Assets | $153.0M |
| Total Assets | $997.0M |
Analysis
Selected assets total $997.0M for Latest. The largest visible component is Short-term Investments at $621.0M, about 62.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $222.0M +48.0% | $150.0M +18.1% | $127.0M -38.3% | $206.0M +39.3% | $147.9M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $759.0M -8.3% | $828.0M +31.0% | $632.0M -21.3% | $803.0M +128.5% | $351.4M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $16.0M -36.0% | $25.0M -40.5% | $42.0M -2.3% | $43.0M -94.2% | $746.8M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $10.0M -23.1% | $13.0M -56.7% | $30.0M +114.3% | $14.0M -4.9% | $14.7M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $1.0B -0.9% | $1.0B +22.3% | $831.0M -22.0% | $1.1B -15.5% | $1.3B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $40.0M -14.9% | $47.0M -7.8% | $51.0M -62.2% | $135.0M -1.8% | $137.4M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $29.0M +107.1% | $14.0M -86.9% | $107.0M -20.1% | $134.0M -27.6% | $185.0M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $63.0M -13.7% | $73.0M -31.1% | $106.0M +960.0% | $10.0M +29.4% | $7.7M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $132.0M -1.5% | $134.0M -49.2% | $264.0M -5.4% | $279.0M -15.5% | $330.1M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $1.1B -1.0% | $1.1B +5.0% | $1.1B -18.6% | $1.3B -15.5% | $1.6B | $13.3B | $11.9B | $10.6B |
| Account Payables | $42.0M +133.3% | $18.0M +5.9% | $17.0M -15.0% | $20.0M +94.9% | $10.3M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 -100.0% | $3.0M -41.2% | $5.1M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $1.0M | $0 | $0 -100.0% | $1.8M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $35.0M -58.8% | $85.0M -6.6% | $91.0M -6.2% | $97.0M -4.9% | $102.0M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $18.0M +28.6% | $14.0M -64.1% | $39.0M -18.8% | $48.0M +58.6% | $30.3M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $231.0M +2.2% | $226.0M +22.8% | $184.0M -4.7% | $193.0M +16.2% | $166.1M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $99.0M +106.3% | $48.0M | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 -100.0% | $234.0M -23.8% | $307.0M -13.5% | $355.0M -23.2% | $462.2M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $178.0M +13.4% | $157.0M +10.6% | $142.0M +517.4% | $23.0M +337.3% | $5.3M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $277.0M -36.9% | $439.0M -2.2% | $449.0M -9.3% | $495.0M -15.3% | $584.4M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $508.0M -23.6% | $665.0M +5.1% | $633.0M -8.0% | $688.0M -8.3% | $750.4M | $14.7B | $3.7B | $9.6B |
| Common Stock | $2.1B +30.9% | $1.6B +23.3% | $1.3B +8.7% | $1.2B +17228471.4% | $7.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.5B -31.2% | -$1.1B -33.3% | -$849.0M -56.6% | -$542.0M -96.8% | -$275.4M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 +100.0% | -$7.0M -455.1% | -$1.3M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $631.0M +30.1% | $485.0M +5.0% | $462.0M -29.7% | $657.0M -21.9% | $841.5M | $9.1B | $7.7B | $3.3B |
| Total Debt | $112.0M +86.7% | $60.0M +445.5% | $11.0M -90.8% | $120.0M -1.6% | $122.0M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$110.0M -22.2% | -$90.0M +22.4% | -$116.0M -34.9% | -$86.0M -231.7% | -$25.9M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.40B
Liquidia Corporation
NASDAQ:LQDA
$6.03B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.87B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.71B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.39B
89bio, Inc.
ETNB
$2.20B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$2.11B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$2.01B
Galapagos N.V.
GLPG
$1.84B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.50B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does RCUS have?
Arcus Biosciences, Inc. (RCUS) reported $222.00M in cash and equivalents in fiscal 2025.
How much debt does RCUS carry?
Arcus Biosciences, Inc. (RCUS) reported $112.00M of total debt, with net debt of -$110,000,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.